On top of expiring Herceptin patents, Roche faces huge royalty losses in 2019
We all know some of Roche’s most valuable patents are expiring soon, not the least of which is the huge revenue-driver cancer drug Herceptin. But …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
